IL6 and pancreatic ductal adenocarcinoma: The ANTXR1 was identified as a functional biomarker of triple-negative breast CSCs, and pancreatic ductal adenocarcinoma (PDAC) patients stratified based on the ANTXR1 expression level showed increased mortality and enrichment of pathways known to be necessary for CSC biology, including TGF-β, NOTCH, Wnt/β-catenin, and IL-6/JAK/STAT3 signaling and epithelial to mesenchymal transition, suggesting that ANTXR1 may represent a putative CSC marker [65].